Evidence map›Paper›PMID 27342654›Full record

Trial reportInternational urology and nephrology2016

Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.

Qijin Zhu, Xiangming Qi, Yonggui Wu, Kun Wang

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Qijin ZhuDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230022, Anhui, China.
Xiangming QiDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230022, Anhui, China.
Yonggui WuDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230022, Anhui, China. wuyonggui@medmail.com.cn.
Kun WangDepartment of Nephrology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230022, Anhui, China.
Anhui Medical University · CNFirst Affiliated Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimTotal glucosides of paeony (TGP), an active compound extracted from dried roots of Paeonia lactiflora Pall, have anti-inflammatory effects. This study investigated the efficacy and safety of TGP for treating diabetic kidney disease (DKD) in type 2 diabetes mellitus patients.

methodsAn open-label, prospective, randomized, parallel-group, single-site study involving 76 patients with DKD. Patients were randomized into two groups: losartan group (n = 38), treated with losartan 100 mg/day for 6 months and TGP group (n = 38), treated with TGP 1800 mg/day and losartan 100 mg/day for 6 months. Serum hs-CRP, MCP-1, and TNF-α were determined before and after treatment. Urinary albumin excretion rate (UAER), fasting blood glucose, serum creatinine, and lipid profiles were examined.

resultsAt the end-point, UAER decreased in the TGP group compared with baseline. UAER in the losartan group decreased to a level lower than before treatment. The rate of decline in the losartan group was significantly lower than the TGP group. There were no significant differences in serum creatinine and albumin levels between TGP and losartan groups at the end-point. Serum hs-CRP, MCP-1, and TNF-α levels were significantly lower in both groups after treatment. After treatment, serum hs-CRP, MCP-1, and TNF-α in the TGP group decreased more than the losartan group. Positive correlations were observed between UAER and hs-CRP, MCP-1, and TNF-α. No statistically significant difference in side effects was observed between groups.

conclusionOur study showed that TGP treatment could reduce the albuminuria and inflammatory markers in type 2 diabetes mellitus patients with DKD.

Indexed as

PaeoniaPhytotherapyAdultAlbuminuriaAntihypertensive AgentsBlood GlucoseChemokine CCL2C-Reactive ProteinCreatinineDiabetes Mellitus, Type 2Diabetic NephropathiesDrug Therapy, CombinationFemaleGlucosidesHumansLosartanAntihypertensive AgentsBlood GlucoseCCL2 protein, humanChemokine CCL2C-Reactive ProteinCreatinineGlucosidesLosartanPlant ExtractsSerum AlbuminTumor Necrosis Factor-alphaAlbumin excretion rateDiabetic kidney diseaseInflammationTotal glucosides of paeony

Identifiers

PMID27342654
OpenAlexW2467464124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.